Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1

10 Feb 2021

Abstract excerpt

BACKGROUND: Camrelizumab, which was launched in China on May 29, 2019, is a humanized anti-programmed cell death-1 (PD-1) antibody. It is used for the treatment of complicated or refractory classic Hodgkin's lymphoma with at least second-line chemotherapy. On March 4, 2020, camrelizumab was approved as a second-line drug in China for the treatment of advanced hepatocellular carcinoma. Currently, camrelizumab is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Phagocytosis and Immune Regulation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33563158
DOI: 10.2174/1574892816666210208231744

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 11 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1PMID 33563158Read ↗

Non-Clinical Evaluation of the Anti-PD-1 Antibody UDIZ-007Semantic proximity Read ↗

A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicitySemantic proximity Read ↗

Next generation of anti-PD-L1 Atezolizumab with better anti-tumor efficacy <i>in vivo</i>Semantic proximity Read ↗

A combination of anti-PD-1 therapy and apatinib successfully treated a patient with EGFR mutation-negative advanced lung adenocarcinoma: A case report.Semantic proximity Read ↗

Camrelizumab In Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Cost-Effective Analysis In ChinaSemantic proximity Read ↗

Efficacy and Safety Analysis of Camrelizumab, Sintilimab, and Tislelizumab in the Treatment of NSCLC in Xuanwei, China: A Retrospective Real-World StudySemantic proximity Read ↗

Relationship between IL-10 and PD-L1 in liver hepatocellular carcinoma tissue and cell linesSemantic proximity Read ↗

Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancersSemantic proximity Read ↗

Clinical significance of circulating biomarkers of immune checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinomaSemantic proximity Read ↗

Antibody-Mediated Therapy in Gastric Cancer: Past, Present, and FutureSemantic proximity Read ↗

Literature analysis of Cadonilimab-induced adverse drug reactionSemantic proximity Read ↗

A phase I study of C-CAR088, a novel humanized anti-BCMA CAR T cell therapy in relapsed/refractory multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.